Merck shares are trading lower after the company announced the discontinuation of the clinical development program evaluating nemtabrutinib, an investigational, oral, non-covalent Bruton’s tyrosine kinase inhibitor.
Merck shares are trading lower after the company announced the discontinuation of the clinical development program evaluating nemtabrutinib, an investigational, oral, non-covalent Bruton’s tyrosine kinase inhibitor.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed